Rangering i aksjer
#17262
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development... Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Handel Invivyd, Inc. (IVVD)
Pris IVVD pris med markedsverdi på B
Markedsverdi av Invivyd, Inc.(IVVD)
Markedsverdi: $257.19M
Per September 2026 har Invivyd, Inc. en markedsverdi på $257.19M. Dette gjør Invivyd, Inc. til det 17262nd mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Invivyd, Inc. fra 2021 til 2026
IVVD sammenlignet med topp 5 mest populære stocks
| Pris på IVVD |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.325T
|
+2,070,162.74%
|
|
|
|
|
$4.773T
|
+1,855,807.39%
|
|
|
|
|
$4.017T
|
+1,561,668.01%
|
|
|
|
|
$3.719T
|
+1,446,022.26%
|
|
|
|
|
$2.743T
|
+1,066,484.12%
|
